Evidence map›Paper›PMID 39726888›Full record

ArticleJournal of biomedical physics & engineering2024

Time Reveals the Truth! What Treatments for COVID-19 Were Quickly Abandoned, and Which Methods, Contrary to Popular Belief, Are Still Flourishing?

Joseph John Bevelacqua, Abdolkarim Ghadimi-Moghadam, Seyed Alireza Mortazavi, Abdollah Jafarzadeh, Masoud Haghani, Azim Kaveh-Ahangar, Ali Ghadimi-Moghadam

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joseph John BevelacquaBevelacqua Resources, Richland, WA, United States.
Abdolkarim Ghadimi-MoghadamPediatric Infectious Ward, Yasuj University of Medical Sciences, Yasuj, Iran.
Seyed Alireza MortazaviSchool of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abdollah JafarzadehDepartment of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Masoud HaghaniDepartment of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Azim Kaveh-AhangarVice-chancellery for Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Ghadimi-MoghadamFaculty of Medicine, Szeged University, Szeged, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the early days of the COVID-19 pandemic, low dose radiation therapy (LDRT) was proposed as a potentially effective treatment method. To minimize potential toxicity, the initial treatment approach involved a few mGy of adapting radiation followed by a single 250 mGy whole lung challenging dose. However, antiviral drugs were also introduced as a promising treatment option, which were thought to have the potential to revolutionize the management of the crisis. Despite early warnings, many physicians did not fully consider the key point that, in contrast with LDRT, antiviral drug treatments can result in strong selective pressure on the virus. This can lead to the emergence of new SARS-CoV-2 variants, a phenomenon that can have serious global consequences. After more than two years, the truth has been revealed the WHO Guideline Development Group has advised against the use of remdesivir, a widely used antiviral medication, for COVID-19. Meanwhile, a growing body of evidence suggests that LDRT can be a promising, low-risk approach for avoiding or delaying invasive respiratory support in COVID-19 patients. Although there is substantial supporting documentation, more high-quality, controlled, and randomized double-blind clinical trials are needed to further investigate the efficacy and potential therapeutic mechanisms of LDRT for COVID-19.

Indexed as

COVID-19Low Dose RadiationPneumoniaRemdesivirSARS-CoV-2

Identifiers

PMID39726888
PMCPMC11668932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.